Yeah, no need to jump off the ride yet. Once Nasdaq main list is achieved, a ten-bagger is in store for those of us who got in early.
Iâve bought through Degiro myself; you can buy from the Frankfurt stock exchange there with about 7e in commission fees.
P.S. Itâs been a nice ride these past few weeks. MINDMED has become the largest holding in my Degiro portfolio, today it was green for the first time in my portfolio at +300%, currently (+297%), with an average price still at 0.5806.
Iâd also be interested to hear more about other similar psychedelic companies. From my limited Googling, Iâve come across other psychedelic companies:
Hollister Biosciences
Revive Therapeutics
COMPASS Pathways.
I havenât looked into those in more detail and donât own any yet.
Champingon Brands Inc. (SHRM) can be bought at least through Nordnetâs phone service. Todayâs daily increase seems to be a hefty 41%. It looks interesting, but itâs quite difficult to do more thorough research on these.
Psychedelic companies are certainly in the green today (too).
Is it the news below or whatâs driving them up? Anyway, today the whole Degiro portfolio is up 14%, due to the recent rises in my largest holding, Mind Medicine. Today I also took an opening position in Red Light Holland Corp, which is also nicely up +70% at the moment.
Iâm very interested in this industry and Mindmed, but like other hype plays, the problem is that I have no idea about target prices and such. I looked into this over a year ago and had the same problem then. Although there wasnât any hype yet. I still have no idea at what price this should be bought and how high the price could be imagined to rise in, for example, 12 months. In these moments, Iâm grateful for Inderesâ follow-ups 
You have to be very careful with these, so you donât jump in at the top of the mountain like with Nikola/GNUS. Then youâll wonder why your position is down -50% the day after buying, and youâll spend the next couple of years trying to break even.
4 Likes
If you follow social media, thereâs a really strong hype and pump going on. Many people are still going to burn their fingers just like they did with cannabis stocks a few years back.
These companies are certainly setting out to solve big problems, and if an effective medicine for even one condition can be brought to market, a lot of money will come in. However, I donât see the current market caps as justified for these companies, as it feels like theyâre springing up like mushrooms after rain out of nowhere.
Mindmed, Numinus, and Compass are definitely companies worth following if the sector interests you. At these prices, though, I wouldnât buy them.
2 Likes
Doesnât this mean that Mind Medicine will receive more funding, and that yesterdayâs +20% increase will be reversed back to the offer price ($4.4) today?
âMind Medicine (NEO: MMED)*** is raising even more cash. The company this evening announced that they have agreed to conduct a $50.0 million bought deal public offering, lead by Canaccord Genuity Corp. The financing is to be conducted at a price of $4.40 per unit, a significant 21.4% discount to todayâs closing price of $5.60.â
1 Like
3 Likes
Looks like a day of gains for this sector! Didnât Numinus have the use of MDMA in PTSD treatment in its portfolio?
1 Like
This is how Iâve understood it. MAPS collaborates with Numinus, utilizing Numinusâ clinics and the âexemptionâ granted by the government to research these treatment methods.
1 Like
3 Likes
Hereâs a bit on the topic, where Finland stands, and what the atmosphere is like.
5 Likes
Quite possibly the first of its kind, a psychedelic ETF will be launched soon with the ticker $PSYK
https://www.psychedelicfinance.com/articles/solactive-publishes-north-american-psychedelic-index-underlier-of-horizons-psyk-etf
Hereâs also a pretty good graph and summary of the sectorâs situation:
https://www.visualcapitalist.com/investors-psyched-about-psychedelic-stocks/
Itâs very challenging to evaluate these, but for example, the Compass team certainly has serious expertise and has already made significant progress in the field of psilocybin-assisted therapy. The big mystery, of course, is what can be patented here, if anything? I personally see a scenario where certain trusted operators are granted special permits/exclusive rights in certain markets to provide psychedelic-assisted services.
2 Likes
For some reason, Nordnet seems to have completely blocked the purchase of MMEDF today. You can sell through a phone broker. Why, I wonder, since trading just became possible through the app..? It has also risen over 13% today due to the news, so itâs incredibly annoying. So weâre again in a situation where we canât reduce holdings in the evening, no matter how much it goes up.
3 Likes
That smells like a bug in NNâs end, which has now been fixed. OTC (Over-The-Counter) stocks should not be able to be bought/sold there, only through phone brokers.
1 Like
A few months ago when I tried to use Nordnet (NN) phone broker, I was told on the phone that from that day on, I no longer needed to call, but purchases and sales could also be done online, and I was directed to the correct application. And yesterday, suddenly, there was a red warning at the top of the Nordnet (NN) page, stating that buying was no longer possible through Nordnet at all, and selling could only be done over the phone. However, the warning has now disappeared, so itâs hard to say if it works or not. Could this somehow be mixed up with wsb-hype stocks, as similar restrictions suddenly appeared for a moment?
I sold a small slice of Mind Media on the 10th and didnât complain about anything then. 
This kind of message from Nordnet, Mindmed on the list.
In accordance with the tightened requirements of the U.S. Securities and Exchange Commission (SEC), the U.S. OTC markets have implemented mandatory risk assessments for all companies listed on the OTC markets. Due to this requirement and new restrictions from Nordnetâs sub-custodian, Nordnet can no longer offer trading (neither buying nor selling) in shares that do not receive an approved risk assessment. See this link for a list of U.S. OTC shares that you can no longer buy through Nordnet and that can no longer be sold after March 31, 2021.
Since Nordnet no longer offers trading in OTC shares that have not received an approved risk assessment, you must sell such holdings before March 31, 2021, at 23:00. You can sell your shares by placing a sell order yourself in Nordnetâs online service. If you have not sold your shares by March 31 at 23:00, you must transfer your OTC shares to another service provider to be able to sell them. After March 31, 2021, you can no longer sell these shares through Nordnet.
1 Like
Argghh, I guess the beginning of this story needs to be looked at least from the listing phase.
Can anyone tell me if Degiro is able to buy this from there and is Degiro otherwise okay?